NC AMVETS Service Foundation Launches CBD Study for Veterans with University of Northern Colorado and Vantage Hemp Co.
January 31, 2024 07:00 ET
|
NC AMVETS Service Foundation
Rockwell, North Carolina, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The North Carolina AMVETS Service Foundation, a 501(c)(3) extension of the state’s most inclusive congressionally chartered veterans...
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 04, 2024 07:00 ET
|
InflaRx N.V.
MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved ≥90%...
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
October 31, 2023 03:00 ET
|
Sosei Group Corporation
NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profileSosei...
Clinical ink Introduces Breakthrough Solution to Drastically Reduce Study Build Timelines
October 12, 2023 06:00 ET
|
Clinical Ink
Winston Salem, NC, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, is setting a new industry benchmark in advancing study build timelines. Harnessing the...
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
September 28, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its...
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
September 27, 2023 07:00 ET
|
CytoSorbents
CytoSorbents summarizes real-world data from STAR Registry analysis being presented next week at European Association of Cardio-Thoracic Surgery Congress
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
September 19, 2023 04:00 ET
|
AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update
September 08, 2023 04:00 ET
|
Adrenomed AG
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
Jupiter Wellness Reports Positive Efficacy Results from Clinical Study for its NoStingz Topical Jellyfish Protection Sunscreen
August 09, 2023 08:45 ET
|
Jupiter Wellness, Inc
Data show NoStingz proprietary formulation provides protection against jellyfish stings including Portuguese man-o’-war JUPITER, FL, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Jupiter Wellness, Inc....
Groundbreaking Study in Nature Digital Medicine Establishes Sword Health’s Digital Physical Therapy Program as the New Gold Standard of Care for the 50 Million Americans Who Endure Physical Pain Daily
July 10, 2023 09:00 ET
|
SWORD Health
NEW YORK, July 10, 2023 (GLOBE NEWSWIRE) -- Today, Sword Health, the world’s first end-to-end platform to predict, prevent and treat pain, is announcing its digital physical therapy program has been...